Most of the current knowledge of relationships between blood levels of quinidine and therapeutic or toxic effects were ascertained by determining peripheral venous levels following oral administration. After single oral administration of quinidine sulfate to patients with atrial fibrillation, Wegria and Boyle (1) observed that the intensity of the cardiac effect of the drug and its plasma concentration were grossly parallel but not parallel in a strictly quantitative manner. Discrepancies were found between the intensity of cardiac effect and quinidine plasma concentration, the plasma level of the drug decreasing faster than the intensity of its cardiac effect. Some investigators utilize quinidine concentration of venous blood as a guide in determining optimal therapy (2-6). Wegria and Boyle (1) reported no significant difference between the arterial and venous concentration of quinidine a few hours after oral administration. Higher levels were found in the myocardium than in the peripheral venous blood.
Most of the current knowledge of relationships between blood levels of quinidine and therapeutic or toxic effects were ascertained by determining peripheral venous levels following oral administration. After single oral administration of quinidine sulfate to patients with atrial fibrillation, Wegria and Boyle (1) observed that the intensity of the cardiac effect of the drug and its plasma concentration were grossly parallel but not parallel in a strictly quantitative manner. Discrepancies were found between the intensity of cardiac effect and quinidine plasma concentration, the plasma level of the drug decreasing faster than the intensity of its cardiac effect. Some investigators utilize quinidine concentration of venous blood as a guide in determining optimal therapy (2-6). Wegria and Boyle (1) reported no significant difference between the arterial and venous concentration of quinidine a few hours after oral administration. Higher levels were found in the myocardium than in the peripheral venous blood.
A recent publication (7) contains a review of the pertinent literature on the subject. In spite of the clinical practice of administering quinidine intravenously to patients with certain life-threatening arrhythmias for immediate therapeutic effects, there is a paucity of data relative to blood levels and these are limited to venous blood (4, 8) .
In the present study of the cardiovascular effects of quinidine given intravenously, levels were determined in specimens obtained from a peripheral vein, artery, coronary sinus and myocardium. Quinidine given intravenously reaches the heart directly, thus bypassing the gastrointestinal tract and liver. We attempted to determine whether a gradient could be demonstrated across the myocardium following such administration. * This work was supported by a grant from the Heart Association of Maryland.
t Postdoctoral Research Fellow of the National Heart Institute.
METHODS
Quinidine gluconate was injected within 1 minute into a cannulated foreleg vein of mongrel dogs anesthetized with sodium pentobarbital. The cannula was kept patent by a drip of heparinized normal saline which was used to flush the injected quinidine into the circulation. Cannulas were inserted into the femoral artery and femoral vein of opposite hind legs for a distance of 5 cm to permit proper collection of specimens. Following cannulation of the opposite femoral artery, the blood pressure was recorded constantly with a Sanborn water manometer or Statham strain gage. Electrocardiograms were continuously recorded. The chest was opened in the right third or fourth intercostal space and a polyethylene tube, small enough not to obstruct the coronary sinus, was inserted into the right atrial appendage and guided into the coronary sinus. After insertion, the tube was sutured to the right atrial Wall at a distance from the coronary sinus. The cannula was initially kept patent by a slow drip of heparinized normal saline. In later studies, coronary sinus blood was often permitted to drip constantly. With the help of 3 observers, specimens were withdrawn simultaneously from the femoral vein, femoral artery and coronary sinus at 1, 3, 5, 10, 15 and 30-minute intervals following injection. The collection of samples was completed within 10 seconds. In some instances, the effects of repeated and prolonged injections were determined. In 5 dogs, ventricular biopsies were obtained at varying intervals following the inj ection of quinidine.
Quinidine levels were determined on whole blood samples by measuring the fluorescence of trichloroacetic acid filtrates, employing the principles of the Linenthal, Ulick and Patterson (9, 10) modification of the Brodie, Udenfriend and Baer technique (11, 12 20 Atg per ml blood. These 60 bloods were analyzed as blind samples and were reported as differences between blood blank and quinidine sample. The mean recovery was 94 per cent, SE 3.9 per cent. Forty specimens were run in quintuplicate. The mean difference of an individual specimen from the mean value of its group was + 2.93 per cent, SD 2.57 per cent. To ascertain that the measured fluorescence represented unconjugated quinidine, parallel samples of the same blood were extracted according to standard procedure in 10 dogs (9-12). The results indicated that over the period of observation there had been no significant conjugation of the quinidine.
All findings are expressed in terms of quinidine base.
RESULTS
Quinidine gluconate was administered rapidly in amounts varying from 2.0 to 15.0 mg per kg body weight.
A. Aramine effectively prevented this drop in pressure.
G. Prolonged injection. When quinidine is given more slowly, there is a gradual rise in the arterial, venous and coronary sinus concentrations until the injection is discontinued (Figure 4) . This results in a more rapid decline in the arterial concentration as compared with the coronary sinus. The level of quinidine in the coronary sinus exceeds the arterial specimen for several minutes. This was observed in three dogs given 11.0 to 14.0 mg per kg over a period of 5 minutes.
DISCUSSION
The intravenous administration of quinidine is usually reserved for emergency use in those patients with certain life-threatening arrhythmias in whom a prompt therapeutic result is required. Most of the available data pertaining to quinidine assay has been obtained after oral, intramuscular or rectal administration (2-4, 9, 13-19). Wegria and Boyle (1) reported no significant differences between the arterial and peripheral venous specimens obtained a few hours after oral administration. Several dogs were sacrificed at hourly intervals following orally administered quinidine. Maximal plasma and tissue quinidine concentrations were reached within 3 hours after ingestion of the drug. Myocardial levels were higher than those of peripheral venous blood. The concentration of quinidine in the left ventricle was 148.6 mg per kg, and in the plasma, 12.5 mg per L 3 hours after 50 mg per kg of quinidine sulfate was given orally. A marked difference persisted up to the final determination at 14 hours.
Sokolow (4) reported that intravenous administration in humans produced high venous levels in a few minutes with the peak subsiding in 5 to 10 minutes. Weisman (20) noted that with a single intravenous dose, less than 6 per cent remained in the blood after 7 minutes. Weiss and Hatcher (21) showed in cats that 95 per cent of an intravenous dose was cleared from the blood in 5 minutes. Kelsey, Oldham and Geiling (22) observed mnyocardial concentrations of quinidine six times greater than in blood in the rabbit 10 minutes after intravenous injection.
To our knowledge, this is the first attempt to measure and demonstrate quinidine arteriovenous and coronary-sinus arterial differences after intravenous injection of quimiidine. There was a fairly wide variation in the blood levels of each animal in spite of the standardization of dose. The variation in the initial arterial level is probably secondary to the rapid change in concentration that occurs shortly after injection. Variations occur in man after the oral administration of quinidine for therapeutic purposes. WNNith increased doses and repeated injections, the blood levels increased and the same general curves resulted. In each dog, the relationships of arterial, venous and coronary sinus levels persisted as described. The The extremely high myocardial concentration of quinidine occurs shortly after injection, as demonstrated by the extremely high initial peak and the subsequent rapid decline. Apparently the quinidine is bound rapidly in the myocardium after the initial period of perfusion and subsequently declines as the blood continues to perfuse the myocardium. Quinidine is also found in high concentrations in other tissues, but the presence of arteriovenous differences across these tissues has not been determined. SUMMARY 1. The rapid intravenous administration of quinidine gluconate in doses of 4.1 to 6.0 mg per kg body weight produces a peak arterial level in 1 minute with a rapid decline within 3 to 5 minutes. In three of six dogs, the quinidine level in the coronary sinus transiently exceeded that in arterial blood following the 1-minute specimen.
2. With the injection of higher doses, the quinidine level in the coronary sinus usually exceeded the arterial level after the first minute.
3. The myocardial concentration of quinidine, following examination of biopsy specimens taken serially in the same animal, exceeded the concentration in the blood from four-to tenfold.
4. It is suggested that quinidine is pooled transiently or bound in the myocardium and is subsequently washed into the coronary sinus.
